Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Candel Therapeutics’ SEC disclosures can feel like decoding lab results—pages packed with virology data, trial endpoints and cash-runway tables. If you’ve ever Googled “Candel Therapeutics insider trading Form 4 transactions” or hunted for a Candel Therapeutics quarterly earnings report 10-Q filing, you know how time-consuming EDGAR can be.
Stock Titan resolves that. Our platform streams Candel Therapeutics Form 4 insider transactions real-time and delivers Candel Therapeutics SEC filings explained simply with AI-powered summaries. One click reveals a concise Candel Therapeutics earnings report filing analysis, while side-by-side comparisons make understanding Candel Therapeutics SEC documents with AI straightforward. We cover every form—10-K, 10-Q, 8-K, S-1 and DEF 14A—and tag key data points as soon as they hit EDGAR, complete with real-time alerts.
Why dig deeper? The Candel Therapeutics annual report 10-K simplified highlights R&D spend, clinical milestones for its adenovirus and HSV platforms, and liquidity runway—critical for biotech valuations. Real-time alerts flag Candel Therapeutics executive stock transactions Form 4, while the Candel Therapeutics proxy statement executive compensation breaks down how leadership incentives align with pipeline progress. Need context on sudden announcements? Get the Candel Therapeutics 8-K material events explained within minutes, including links to new trial data and secondary offerings. With AI-powered summaries, real-time updates and focused biotech expertise, you’ll move from raw documents to actionable insight before the market reacts.
Candel Therapeutics Chief Technology Officer Seshu Tyagarajan acquired 5,353 shares of common stock on June 25, 2025, through a registered direct offering at a price of $4.67 per share. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025.
Following the transaction, Tyagarajan directly owns 90,865 shares of the company's common stock. The Form 4 filing indicates this was a direct ownership acquisition with no derivative securities involved in the transaction.
- Transaction Type: Registered Direct Offering Purchase
- Total Transaction Value: Approximately $25,000
- Filing was made within the required two-business-day reporting window
- Transaction was executed through proper documentation and authorization via attorney-in-fact
Candel Therapeutics (CADL) reported a significant insider purchase by CEO and Director Paul Peter Tak on June 25, 2025. The transaction involved the acquisition of 42,826 shares at $4.67 per share through a registered direct offering, representing a total investment of approximately $200,000.
Following this transaction, Tak's direct beneficial ownership increased to 268,566 shares. The purchase was executed pursuant to a Securities Purchase Agreement dated June 23, 2025, demonstrating insider confidence in the company's prospects.
Key Transaction Details:
- Transaction Type: Direct Purchase (registered offering)
- Share Price: $4.67
- Total Shares Post-Transaction: 268,566
- Filing Date: June 28, 2025
- Transaction Form: Form 4 (Statement of Changes in Beneficial Ownership)
Paul B. Manning, Director of Candel Therapeutics (CADL), reported significant insider transactions on June 25, 2025. Manning acquired 1,070,663 shares at $4.67 per share through a registered direct offering, demonstrating substantial insider investment totaling approximately $5 million.
Following the transaction, Manning's beneficial ownership includes:
- 2,213,069 shares held indirectly through the Paul B. Manning Revocable Trust
- 1,303,752 shares held indirectly through BKB Growth Investments, LLC
- 1,681,000 shares held directly (jointly with spouse)
The total beneficial ownership amounts to 5,197,821 shares, indicating significant insider confidence in the company. The purchase was made pursuant to a Securities Purchase Agreement dated June 23, 2025, suggesting a planned strategic investment in the company's future.
Christopher Martell, Director of Candel Therapeutics (CADL), reported significant insider transactions and holdings on June 28, 2025:
Key Transaction: Acquired 111,349 shares of Common Stock at $4.67 per share on June 25, 2025, through a registered direct offering. These shares are held indirectly through his spouse.
Additional Indirect Holdings:
- 152,000 shares held through GTAM1 2012 LLC (trust where Martell serves as trustee)
- 283,514 shares held through GTAM1 2012 ADV LLC (where Martell serves as manager)
Total beneficial ownership across all indirect holdings amounts to 546,863 shares. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025. Martell disclaims beneficial ownership of trust-held shares except for his pecuniary interest.
Director Nicoletta Loggia of Candel Therapeutics (NASDAQ: CADL) reported the acquisition of 2,141 shares of common stock on June 25, 2025. The shares were purchased at $4.67 per share through a registered direct offering, resulting in a total investment of approximately $10,000.
The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025. Following the reported transaction, Loggia directly owns 2,141 shares of Candel Therapeutics common stock.
Key Transaction Details:
- Transaction Type: Direct Purchase through Registered Offering
- Share Price: $4.67
- Total Shares Acquired: 2,141
- Ownership Type: Direct
- Filing Date: June 28, 2025
Charles Schoch, Chief Financial Officer of Candel Therapeutics (CADL), reported acquiring 5,353 shares of Common Stock on June 25, 2025, at a price of $4.67 per share through a registered direct offering. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025.
Following this transaction, Schoch's direct beneficial ownership increased to 43,391 shares. The acquisition was made through a registered direct offering, indicating a structured investment in the company by its CFO.
- Transaction Type: Direct Purchase (Form Code: A)
- Transaction Value: Approximately $25,000
- Ownership Form: Direct
- No derivative securities were involved in this transaction
Insider Trading Alert: Gary J. Nabel, Director of Candel Therapeutics (NASDAQ: CADL), acquired 5,353 shares of common stock on June 25, 2025, at a price of $4.67 per share. The total transaction value amounts to approximately $25,000.
The shares were acquired through a registered direct offering pursuant to a Securities Purchase Agreement dated June 23, 2025. Following the transaction, Nabel directly owns 5,353 shares of Candel Therapeutics.
This Form 4 filing, submitted on June 28, 2025, represents a direct purchase of shares by a company insider, potentially signaling confidence in the company's prospects. The transaction was executed through an attorney-in-fact, Charles Schoch, who signed the filing on Nabel's behalf.
Candel Therapeutics Chief Scientific Officer Francesca Barone acquired 4,282 shares of common stock on June 25, 2025, through a registered direct offering at a price of $4.67 per share. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025.
Following this acquisition, Barone now directly owns 100,809 shares of the company's common stock. The Form 4 filing indicates this was a direct ownership transaction, with no derivative securities involved.
- Transaction Type: Registered Direct Offering Purchase
- Total Transaction Value: $19,996.94
- Filing Status: Individual filing by reporting person
- Position: Chief Scientific Officer (Executive Officer)
Insider Trading Alert: Joseph C. Papa, Director of Candel Therapeutics (NASDAQ: CADL), acquired 64,239 shares of common stock on June 25, 2025, through a registered direct offering at $4.67 per share. The transaction was executed through the Joseph C. Papa Revocable Living Trust.
Key Transaction Details:
- Total shares acquired: 64,239 shares
- Purchase price: $4.67 per share
- Transaction value: approximately $300,000
- Post-transaction holdings: 64,239 shares (indirect) + 38,032 shares (direct)
The acquisition was made pursuant to a Securities Purchase Agreement dated June 23, 2025. The shares are held indirectly through a trust arrangement, with Papa serving as trustee. This insider purchase may signal management's confidence in the company's prospects.
Candel Therapeutics, Inc. (CADL) – Form 4 filing dated 06/24/2025
The company’s Chief Financial Officer, Charles Schoch, reported the grant of a stock option for 50,000 shares of common stock with an exercise price of $4.75 per share. The option was issued on 06/20/2025 and will expire on 06/20/2035.
Vesting schedule: 25 % of the award vests on 06/20/2026; the remaining 75 % vests in 36 equal monthly installments thereafter, contingent on continued service.
Following this transaction, Mr. Schoch beneficially owns 50,000 derivative securities (stock options) directly. No open-market purchases or sales of CADL common shares were disclosed.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
What is the core focus of Candel Therapeutics, Inc.?
What therapeutic platforms does the company use?
Which types of cancer are being targeted by their therapies?
How does Candel Therapeutics differentiate itself from other oncology companies?
What stage are the company’s product candidates currently in?
How does the company ensure the scientific rigor of its research?
What role does immuno-oncology play in their overall strategy?
How is Candel Therapeutics positioned within the competitive biopharmaceutical sector?
